Endoscopic Metabolic Surgery Through Reduced-Access Techniques

Abstract

Endoscopic metabolic surgery through reduced-access techniques represents a paradigm shift in the management of obesity and metabolic syndrome, offering less invasive alternatives to traditional bariatric surgery. This article reviews current evidence on the efficacy, safety, and clinical utility of endoscopic metabolic interventions, summarizing mechanisms, indications, outcomes, and future directions for this rapidly evolving field. The review is intended for clinicians and healthcare professionals seeking up-to-date, evidence-based insights on this innovative approach.

Introduction

The global rise in obesity and metabolic syndrome has intensified the search for effective, durable, and minimally invasive interventions. Traditional bariatric surgery, though effective, is associated with surgical risks and postoperative morbidity. Endoscopic metabolic surgery (EMS) using reduced-access techniques has emerged as a promising alternative, aiming to replicate the metabolic benefits of conventional surgery with fewer complications, faster recovery, and broader applicability. This review synthesizes the current landscape of EMS, focusing on clinical evidence, mechanisms of action, and practical considerations for integration into metabolic disease management.

Epidemiology / Disease Burden

Obesity affects over 650 million adults worldwide, with substantial associated morbidity from type 2 diabetes mellitus (T2DM), cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD). Conventional lifestyle and pharmacological therapies often fail to achieve sustained weight loss, rendering surgical interventions a mainstay for severe cases. However, less than 2% of eligible patients undergo bariatric surgery due to invasiveness, cost, and limited access. Reduced-access endoscopic approaches have the potential to bridge this treatment gap, targeting the vast population of patients with moderate obesity and metabolic syndrome not suited for or willing to undergo surgery.

Pathophysiology

Obesity and metabolic syndrome arise from a complex interplay of genetic, environmental, and behavioral factors leading to adiposity, insulin resistance, and systemic inflammation. Traditional bariatric procedures, such as Roux-en-Y gastric bypass and sleeve gastrectomy, induce weight loss and metabolic improvements through restriction, malabsorption, and hormonal modulation (e.g., increased GLP-1, altered bile acid signaling). Endoscopic metabolic procedures aim to reproduce these effects by targeting the gastrointestinal tract via mucosal ablation, sleeve creation, or bypass without the need for major surgery.

Risk Factors

Risk factors for obesity and metabolic syndrome include genetic predisposition, high-calorie diet, sedentary lifestyle, socioeconomic status, and certain medications. Patients with BMI >30 kg/m², especially those with comorbidities like T2DM or hypertension, are primary candidates for metabolic intervention. Identifying individuals who may benefit most from endoscopic metabolic surgery involves assessing not only BMI but also metabolic health, previous weight loss failures, and risk profiles for traditional surgery.

Clinical Features

Obesity presents with progressive weight gain, central adiposity, and complications such as impaired glucose tolerance, dyslipidemia, hypertension, and NAFLD. Clinical features of metabolic syndrome include abdominal obesity, hyperglycemia, elevated triglycerides, low HDL cholesterol, and hypertension. The impact on quality of life and long-term morbidity underscores the need for effective interventions beyond lifestyle modification and pharmacotherapy.

Diagnosis

Diagnosis of obesity and metabolic syndrome relies on anthropometric measurements (BMI, waist circumference), laboratory evaluation (fasting glucose, lipid profile), and assessment of comorbidities. For patient selection, comprehensive medical evaluation, endoscopic assessment of the gastrointestinal tract, and multidisciplinary review are essential to exclude contraindications and optimize outcomes with endoscopic metabolic procedures.

Treatment & Management

Traditional management includes lifestyle intervention, behavioral therapy, and pharmacologic agents (e.g., GLP-1 agonists, SGLT2 inhibitors, orlistat). Bariatric surgery remains the gold standard for sustained weight loss in severe obesity. Endoscopic metabolic surgery offers a minimally invasive option, with procedures such as intragastric balloons, endoscopic sleeve gastroplasty (ESG), duodenal mucosal resurfacing (DMR), and endoluminal bypass sleeves. These interventions promote weight loss, improve glycemic control, and are associated with reduced perioperative risks and faster recovery. Patient selection, procedural expertise, and comprehensive aftercare are critical for optimizing safety and efficacy.

Recent Advances / Emerging Therapies

Recent advances in EMS include novel devices and techniques, such as the Apollo ESG, Primary Obesity Surgery Endoluminal (POSE), DMR, and duodenal-jejunal bypass liners. Randomized controlled trials have demonstrated significant weight loss (15–20% total body weight loss at 12–24 months) and improvements in HbA1c, especially with ESG and DMR. Innovations in device design, procedural safety, and durability of metabolic benefits continue to expand indications and facilitate adoption. Ongoing studies are investigating combination therapies and the long-term impact on cardiovascular outcomes.

Guideline Recommendations

Leading societies, including the American Society for Gastrointestinal Endoscopy (ASGE) and the International Federation for the Surgery of Obesity (IFSO), now endorse endoscopic metabolic procedures for patients with BMI 30–40 kg/m² who have failed lifestyle or pharmacological therapy, and those unfit for or unwilling to undergo surgery. Guidelines emphasize the need for multidisciplinary evaluation, informed consent, standardized protocols, and participation in registries to enhance evidence generation and procedural quality control.

Conclusion

Endoscopic metabolic surgery through reduced-access techniques represents a transformative development in obesity and metabolic syndrome management, offering safe, effective, and less invasive alternatives to conventional surgery. While long-term data and head-to-head comparative studies are needed, emerging evidence supports the clinical utility of these procedures in selected patients. Integration into multidisciplinary care pathways, adherence to guideline recommendations, and ongoing research will be pivotal in optimizing outcomes and expanding access to this promising intervention.